Reuters logo
BRIEF-Conatus to receive $50 mln in liver drug deal with Novartis
December 19, 2016 / 10:23 PM / 9 months ago

BRIEF-Conatus to receive $50 mln in liver drug deal with Novartis

Dec 19 (Reuters) - Conatus Pharmaceuticals Inc :

* Conatus Pharmaceuticals Inc says full funding in position for remaining development of Emricasan

* Conatus Pharmaceuticals Inc- Conatus can borrow up to $15 million in form of convertible promissory notes under an investment agreement with Novartis

* Conatus Pharmaceuticals Inc - Novartis will pay 50 pct of Conatus’ Phase 2B Emricasan development costs after option exercise

* Conatus Pharmaceuticals Inc - Novartis will assume full responsibility for Emricasan’s Phase 3 development and all combination product development

* Conatus Announces exclusive worldwide option, collaboration and license agreement covering development and commercialization of emricasan

* Conatus pharmaceuticals inc says continuing initial focus on nash cirrhosis with parallel development in nash fibrosis

* Conatus Pharmaceuticals Inc - is eligible to receive $7 million following exercise of license option

* Conatus Pharmaceuticals Inc - “for conatus, near-term infusion of capital and phase 2B cost-sharing allows us to fund ongoing operations through 2019”

* Conatus Pharmaceuticals Inc says planned phase 2B ENCORE-LF clinical trial with composite clinical endpoint, expected to begin in first half of 2017

* Press release - Conatus announces exclusive worldwide option, collaboration and license agreement covering development and commercialization of emricasan Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below